The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma

Purpose: Although the translocation t(4;14) is supposed to be a primary event in multiple myeloma, we have been surprised to observe that in large relapse series of patients, the t(4;14) can be observed only in subpopulations of plasma cells, in contrast to what is seen at diagnosis. This observation raised the question of possible subclones harboring the translocation that would be observable only at the time of relapse. Experimental Design: To address this issue, we analyzed by FISH a cohort of 306 patients for whom we had at least two samples obtained at different disease phases. Results: We observed a “gain” of the t(4;14) in 14 patients, and conversely, a “loss” of the translocation in 11 patients. Two hypotheses were raised: either an acquisition of the translocation during evolution or the existence of small t(4;14)-positive subclones at the time of diagnosis. To address this question, we had the opportunity to analyze two patients at the time of diagnosis by RT-PCR (reverse transcription-polymerase chain reaction) to look for the chimeric Eμ-MMSET transcript, and one patient positive at diagnosis, but negative at relapse. The samples were positive, supporting the second hypothesis. Furthermore, the IGH sequences of two patients who “lose” the t(4;14) were identical at diagnosis and relapse, confirming the existence of a common ancestral clone. Conclusion: Thus, the conclusion of this study is that the t(4;14) is not a primary event in multiple myeloma and that it can be present in silent subclones at diagnosis, but also at relapse. Clin Cancer Res; 19(17); 4634–7. ©2013 AACR.

[1]  N. Munshi,et al.  Minor clone provides a reservoir for relapse in multiple myeloma , 2013, Leukemia.

[2]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[3]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[4]  G. Morgan,et al.  The genetic architecture of multiple myeloma , 2012, Nature Reviews Cancer.

[5]  A. Kenneth,et al.  Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Sonneveld,et al.  Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. , 2010, Blood.

[7]  B. Barlogie,et al.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[8]  B. Barlogie,et al.  The molecular characterization and clinical management of multiple myeloma in the post-genome era , 2009, Leukemia.

[9]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[10]  John D. Shaughnessy,et al.  High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. , 2008, Blood.

[11]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[12]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[13]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[14]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[15]  L. Baldini,et al.  Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. , 2000, Cancer research.